40925-70-0

Usage

Uses

Used in Dye Manufacturing:
2-Amino-5-methoxy-phenol is used as a key intermediate in the production of dyes. Its unique chemical structure allows it to contribute to the color and stability of various dye formulations, making it an essential component in the dye industry.
Used in Chemical Research:
Due to its distinctive properties, 2-Amino-5-methoxy-phenol is also utilized in chemical research for the synthesis of other organic compounds and as a model compound to study the reactivity and behavior of similar aromatic amines.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, the compound's chemical structure suggests potential applications in the pharmaceutical industry, where it could be used as a building block for the development of new drugs or as a reagent in the synthesis of pharmaceutical compounds. However, further research and development would be required to explore these possibilities.

Upstream product

• 56661-22-4 2-hydroxy-4-methoxyazobenzene 
• 13895-38-0 2-nitroso-5-methoxyphenol 
• 7647-01-0 hydrogenchloride 
• 58243-21-3 5-methoxy-1,2-naphthoquinone-2-oxime 
• 446-36-6 5-fluoro-2-nitrophenol 
• 150-19-6 O-methylresorcine 
• 2051-85-6 4-(phenylazo)-1,3-benzenediol 
• 704-14-3 3-methoxy-6-nitro-phenol 
• 91-66-7 N,N-diethylaniline 
• 89232-58-6 O-(3-methoxyphenyl)hydroxylamine 

Downstream Products

• 112808-53-4 2-(2-bromo-3-methylbutyryl)amino-5-methoxyphenol 
• 88972-91-2 2,6-Di-tert-butyl-4-(6-methoxy-benzooxazol-2-yl)-phenol 
• 532-91-2 coixol 
• 99141-30-7 3-(1-imidazoyl)-6-methoxy-2-benzoxazolinone 
• 221060-78-2 2-bromo-N-(2-hydroxy-4-methoxyphenyl)-5-methyl-3-thiophenecarboxamide 
• 6529-91-5 2-chloro-N-(2-hydroxy-4-methoxyphenyl)acetamide 
• 101908-49-0 N-(2-hydroxy-4-methoxyphenyl)propanamide 
• 77791-12-9 6-methoxy-2-phenyl-1,3-benzoxazole 
• 114980-26-6 6-methoxybenzoxazole 
• 477601-28-8 6-methoxy-quinolin-8-ol 
• 56317-21-6 moracin M 

Relevant academic research and scientific papers

A Facile Synthesis of 6-Methoxy-2-oxo-2,3-dihydrobenzoxazole

A new two-step synthesis of 6-methoxybenzoxazolin-2(3H)-one, a bioactive natural product from Gramineae, is described.The new procedure avoids disadvantages of hitherto existing methods and affords the title compound in 75percent yield from 5-methoxy-2-ni

Design, synthesis and biological evaluation of benz-fused five-membered heterocyclic compounds as tubulin polymerization inhibitors with anticancer activities

A series of benz-fused five-membered heterocyclic compounds were designed and synthesized as novel tubulin inhibitors targeting the colchicine binding site. Among them, compound 4d displayed the highest antiproliferative activity against four cancer cell lines with an IC50 value of 4.9?μM in B16-F10 cells. Compound 4d effectively inhibited tubulin polymerization in vitro (IC50 of 13.1?μM). Further, 4d induced cell cycle arrest in G2/M phase. Finally, 4d inhibited the migration of cancer cells in a dose-dependent manner. In summary, these results suggest that compound 4d represents a new class of tubulin inhibitors deserving further investigation.

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

Tris(2-carboxyethyl)phosphine promotes hydrolysis of iminoboronates

Iminoboronates are stable and formed fast. Their B[sbnd]N bonds could be reverted by some endogenous biological molecules. The reversible characteristic attracts significant attention in biological and chemical fields. Although synthesis of iminoboronates is well-studied, less efforts have been devoted to disconnecting the units. Here, a series of selected compounds were screened to evaluate their hydrolytic capability of iminoboronates by 1H NMR or 11B NMR detection. Tris(2-carboxyethyl)phosphine (TCEP), was emerged as an excellent reagent, which decomposed most iminoboronates in short time with high yields. In addition, TCEP is also able to hydrolyze hydrazones and oximes with moderate yields.

HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors

A novel series of benzoxazole analogs was designed and synthesized, and their inhibitory activities against Aurora kinases were evaluated. Some of the tested compounds exhibited a promising activity with respect to the inhibition of Aurora B kinase. A structure-activity relationship study indicated that linker length, regiochemistry, and halogen substitution play important roles in kinase inhibitory potency. The binding modes between representative compounds and Aurora kinases were interpreted through a molecular docking study to explain the inhibitory activity and selectivity for Aurora A and B kinases. Compounds 13l and 13q also show an antiproliferative effect on the human tumor cell lines in a dose-dependent manner. The most potent 13q demonstrated good efficacy in the prostate cancer PC-3 tumor xenograft model.

Analgesic Compounds, Compositions, and Uses Thereof

The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

Optimization of the azobenzene scaffold for reductive cleavage by dithionite; development of an azobenzene cleavable linker for proteomic applications

In this paper we conducted an extensive reactivity study to determine the key structural features that favour the dithionite-triggered reductive cleavage of the azo-arene group. Our stepwise investigation allowed identification of a highly reactive azo-arene structure 25 bearing a carboxylic acid, at the ortho position of the electron-poor arene and an ortho-Oalkyl-resorcinol as the electron-rich arene. Based on this 2(2′-alkoxy-4′-hydroxyphenylazo) benzoic acid (HAZA) scaffold, the orthogonally protected difunctional azo-arene cleavable linker 26 was designed and synthesized. Selective linker deprotection and derivatization was performed by introducing an alkyne reactive group and a biotin affinity tag. This optimized azo-arene cleavable linker led to a total cleavage in less than 10 s with only 1 mM dithionite. Similar results were obtained in biological media.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.